ZVRA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

28.05M

+132.94%

0.050

-107.25%

32.25M

+58.09%

0.104

-273.33%

35.47M

+37.05%

0.144

-88.1%

Estimates Revision

The market is revising Downward the revenue expectations for Zevra Therapeutics, Inc. (ZVRA) for FY2025, with the revenue forecasts being adjusted by -0.65% over the past three months. During the same period, the stock price has changed by -22.89%.

Revenue Estimates for FY2025

Revise Downward

-0.65%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-22.89%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24.00 USD with a low forecast of 21.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

24.00

High

26.00

Current: 0.000

Low

21.00

Averages

24.00

High

26.00

H.C. Wainwright

Buy

maintain

$26

2025-12-30

Reason

H.C. Wainwright

Price Target

$26

2025-12-30

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating on Zevra Therapeutics (ZVRA) with a $26 price target after the company signed an exclusive expanded access distribution agreement with Uniphar (UPR). The deal adds new territories to Zevra's current expanded access program for Miplyffa for Niemann-Pick disease type C patients, the analyst tells investors in a research note. H.C. Wainwright believes the expanded opportunity for Miplyffa is currently not priced into the stock or reflected in consensus expectations.

Canaccord

Buy

downgrade

$25 -> $24

2025-11-06

Reason

Canaccord

Price Target

$25 -> $24

2025-11-06

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Zevra Therapeutics to $24 from $25 and keeps a Buy rating on the shares. The firm lowered its target on a softening Europe Miplyffa ramp.

Cantor Fitzgerald

Kristen Kluska

Overweight

downgrade

$29 -> $24

2025-11-06

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$29 -> $24

2025-11-06

downgrade

Overweight

Reason

Cantor Fitzgerald analyst Kristen Kluska lowered the firm's price target on Zevra Therapeutics to $24 from $29 and keeps an Overweight rating on the shares.

Citizens JMP

Jason Butler

Outperform

downgrade

$19 -> $18

2025-08-13

Reason

Citizens JMP

Jason Butler

Price Target

$19 -> $18

2025-08-13

downgrade

Outperform

Reason

Citizens JMP analyst Jason Butler lowered the firm's price target on Zevra Therapeutics to $18 from $19 and keeps an Outperform rating on the shares. The MIPLYFFA launch continues to outpace expectations, with Q2 U.S. sales of $21.5M, exceeding expectations, with management noting that there have been 129 total patient enrollment forms received to date, up 7 from 122 at the end of March, the analyst tells investors in a research note. Zevra is well-funded to achieve positive cash flow, the firm adds.

Cantor Fitzgerald

NULL -> Overweight

maintain

$25 -> $29

2025-07-10

Reason

Cantor Fitzgerald

Price Target

$25 -> $29

2025-07-10

maintain

NULL -> Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Zevra Therapeutics to $29 from $25 and keeps an Overweight rating on the shares. Miplyffa stands a good chance of approval in the EU, the analyst tells investors in a research note.

H.C. Wainwright

initiated

$26

2025-07-02

Reason

H.C. Wainwright

Price Target

$26

2025-07-02

initiated

Reason

H.C. Wainwright initiated coverage of Zevra Therapeutics with a Buy rating and $26 price target. Zevra has successfully launched Miplyffa for Niemann-Pick disease type C in the U.S. and the firm sees \"multiple levers for further long term value creation,\" the analyst tells investors. Even with the success of Miplyffa in the U.S., the firm believes the stock \"remains undervalued on the Miplyffa U.S. opportunity alone,\" the analyst added.

Valuation Metrics

The current forward P/E ratio for Zevra Therapeutics Inc (ZVRA.O) is 17.82, compared to its 5-year average forward P/E of -4.89. For a more detailed relative valuation and DCF analysis to assess Zevra Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.89

Current PE

17.82

Overvalued PE

27.69

Undervalued PE

-37.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-2.75

Current EV/EBITDA

11.80

Overvalued EV/EBITDA

22.57

Undervalued EV/EBITDA

-28.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

9.63

Current PS

3.51

Overvalued PS

17.00

Undervalued PS

2.27

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ZVRA News & Events

Events Timeline

No data

News

5.0

2025-12-28Yahoo Finance

Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss

5.0

2025-12-12Newsfilter

Zevra Grants 53,000 Stock Options to Attract New Employees

3.0

2025-11-03Benzinga

Key Stocks Reporting Earnings This Week: Joby, IonQ, AMD, and Others

People Also Watch

Frequently Asked Questions

What is Zevra Therapeutics Inc (ZVRA) stock price today?

The current price of ZVRA is 8.49 USD — it has decreased -1.62 % in the last trading day.

What is Zevra Therapeutics Inc (ZVRA)'s business?

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.

What is the price predicton of ZVRA Stock?

What is Zevra Therapeutics Inc (ZVRA)'s revenue for the last quarter?

Zevra Therapeutics Inc revenue for the last quarter amounts to 26.06M USD, increased 605.36 % YoY.

What is Zevra Therapeutics Inc (ZVRA)'s earnings per share (EPS) for the last quarter?

Zevra Therapeutics Inc. EPS for the last quarter amounts to -0.01 USD, decreased -98.55 % YoY.

What changes have occurred in the market's expectations for Zevra Therapeutics Inc (ZVRA)'s fundamentals?

How many employees does Zevra Therapeutics Inc (ZVRA). have?

Zevra Therapeutics Inc (ZVRA) has 59 emplpoyees as of January 10 2026.

What is Zevra Therapeutics Inc (ZVRA) market cap?

Today ZVRA has the market capitalization of 477.97M USD.